Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: Twelve-month outcomes of a phase III study

Ophthalmology

Volumn 118, Issue 10, 2011, Pages 2041-2049

  Campochiaro, Peter A ^a   Brown, David M ^b   Awh, Carl C ^c   Lee, S Young ^d   Gray, Sarah ^e   Saroj, Namrata ^e   Murahashi, Wendy Yee ^e   Rubio, Roman G ^e  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Retinal Consultants of Houston   (United States)

^c Tennessee Retina   (United States)

^d Retina Research Institute of Texas   (United States)

^e GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RANIBIZUMAB; VASCULOTROPIN INHIBITOR;

ADULT; ANGINA PECTORIS; ARTICLE; BRAIN ISCHEMIA; CATARACT; CENTRAL RETINA VEIN OCCLUSION; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; EYE DISEASE; EYE INFLAMMATION; HEART INFARCTION; HUMAN; IRIDOCYCLITIS; IRIS NEOVASCULARIZATION; IRITIS; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NEOVASCULAR GLAUCOMA; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RETINA FOVEA; RETINA MACULA EDEMA; RETINA TEAR; SHAM PROCEDURE; THICKNESS; TRANSIENT ISCHEMIC ATTACK; TREATMENT DURATION; VISION; VISUAL ACUITY; VITREOUS HEMORRHAGE; VITRITIS;

ADOLESCENT; ANTIBODIES, MONOCLONAL, HUMANIZED; DOUBLE-BLIND METHOD; FLUORESCEIN ANGIOGRAPHY; HUMANS; INJECTIONS, INTRAOCULAR; MACULAR EDEMA; PROSPECTIVE STUDIES; RETINAL VEIN OCCLUSION; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VISUAL ACUITY; YOUNG ADULT;

EID: 79958843614     PISSN: 01616420     EISSN: 15494713     Source Type: Journal    
DOI: 10.1016/j.ophtha.2011.02.038     Document Type: Article

References (10)

1. R. Klein, S.E. Moss, S.M. Meuer, and B.E. Klein The 15-year cumulative incidence of retinal vein occlusion: the Beaver Dam Eye Study Arch Ophthalmol 126 2008 513 518 (Pubitemid 351549845)
2. P. Mitchell, W. Smith, and A. Chang Prevalence and associations of retinal vein occlusion in Australia: the Blue Mountains Eye Study Arch Ophthalmol 114 1996 1243 1247 (Pubitemid 26338856)
3. W.R. Green, C.C. Chan, G.M. Hutchins, and J.M. Terry Central vein occlusion: a prospective histological study of 29 eyes in 28 cases Trans Am Ophthalmol Soc 79 1981 371 422
4. P.A. Campochiaro, G. Hafiz, and S.M. Shah Ranibizumab for macular edema due to retinal vein occlusions: implication of VEGF as a critical stimulator Mol Ther 16 2008 791 799 (Pubitemid 351426182)
5. R.F. Spaide, L.K. Chang, and J.M. Klancnik Prospective study of intravitreal ranibizumab as a treatment for decreased visual acuity secondary to central retinal vein occlusion Am J Ophthalmol 147 2009 298 306
6. D.J. Pieramici, M. Rabena, and A.A. Castellarin Ranibizumab for the treatment of macular edema associated with perfused central retinal vein occlusions [report online] Ophthalmology 115 2008 e47 e54 http://www. ophthalmologyjournaloftheaao.com/article/S0161-6420%2808%2900634-9/abstract Accessed February 21, 2011
7. D.M. Brown, P.A. Campochiaro, R.P. Singh CRUISE Investigators Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study Ophthalmology 117 2010 1124 1133
8. P.A. Campochiaro, J.S. Heier, L. Feiner BRAVO Investigators Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary endpoint results of a phase III study Ophthalmology 117 2010 1102 1112
9. Antiplatelet Trialists' Collaboration Collaborative overview of randomised trials of antiplatelet therapyI: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients BMJ 308 1994 81 106
10. P.A. Campochiaro, G. Hafiz, and R. Channa Antagonism of vascular endothelial growth factor for macular edema caused by retinal vein occlusion: two-year outcomes Ophthalmology 117 2010 2387 2394